Brophy Wealth Management LLC Takes $809,000 Position in United Therapeutics Co. (NASDAQ:UTHR)

Brophy Wealth Management LLC acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 2,258 shares of the biotechnology company’s stock, valued at approximately $809,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. ClariVest Asset Management LLC boosted its holdings in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of United Therapeutics during the second quarter valued at about $30,000. Innealta Capital LLC bought a new stake in shares of United Therapeutics during the second quarter worth about $33,000. USA Financial Formulas acquired a new position in shares of United Therapeutics in the third quarter valued at approximately $33,000. Finally, Brooklyn Investment Group bought a new position in United Therapeutics in the 3rd quarter valued at approximately $33,000. Institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, Director Christopher Causey sold 510 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total transaction of $192,081.30. Following the completion of the sale, the director now directly owns 3,675 shares of the company’s stock, valued at $1,384,115.25. The trade was a 12.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Judy D. Olian sold 1,750 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $412.48, for a total transaction of $721,840.00. Following the completion of the transaction, the director now directly owns 5,655 shares in the company, valued at approximately $2,332,574.40. The trade was a 23.63 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 119,340 shares of company stock worth $44,765,530. 11.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. The Goldman Sachs Group upped their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. HC Wainwright increased their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. TD Cowen lifted their target price on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, October 21st. StockNews.com raised United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, Jefferies Financial Group lifted their price objective on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $370.86.

United Therapeutics Price Performance

Shares of UTHR opened at $367.00 on Tuesday. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82. The company has a market cap of $16.39 billion, a PE ratio of 16.12, a P/E/G ratio of 1.07 and a beta of 0.55. The stock has a 50-day moving average of $369.31 and a 200-day moving average of $340.14.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same quarter in the previous year, the company posted $5.38 earnings per share. The company’s quarterly revenue was up 22.9% on a year-over-year basis. Analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.